Acquisition Synergy Biologics, Inc. is now part of McKesson Corporation, creating an opportunity to align oncology specialty pharmacy capabilities with McKesson’s broader healthcare services and IT solutions to accelerate access to therapies and expand joint offerings.

Oncology Focus The company has a strong oncology orientation with multiple partnerships and launches (Taiho Oncology, CABLIVI, TARPEYO) and exclusive specialty pharmacy arrangements for complex therapies, suggesting a prime upsell path for advanced cancer treatments and associated patient support programs.

Patient Access Programs Recent initiatives include full-service patient support programs and access services designed to shorten time to therapy, presenting opportunities to expand patient navigation, reimbursement support, and co-pay assistance collaborations with pharma partners.

Strategic Partnerships Notable client wins (Sanofi, Lexpharma) and high-profile therapy launches indicate a track record of securing strategic distribution and limited-disupply network arrangements, signaling upsell potential in managed care access, specialty distribution, and clinical services.

Growth Signals Revenue range indicates a mid-market specialty pharmacy with room to scale; integration with McKesson can leverage larger customer base, enhanced IT and analytics capabilities, and expanded portfolio to pursue broader complex-therapy opportunities and cross-sell across health system customers.